Korovina E P
Klin Med (Mosk). 1998;76(12):30-5.
Effects of beta-blockers (propranolol, penbutolol) and calcium antagonists (nifedipine, verapamil, diltiazem) were studied in 73 patients with hypertrophic cardiomyopathy (HC). Clinical data, ECG and echo-CG findings were assessed. It was found that beta-adrenoblockers and calcium antagonists improve quality of life in one-third of the patients. Penbutolol and nifedipine did so in half of the patients. Neither beta-adrenoblockers nor calcium antagonists decrease myocardial hypertrophy. Calcium antagonists may result in lowering of myocardial contractility while beta-adrenoblockers may increase the ejection fraction. Diltiazem produced a positive effect on diastolic function but had many side effects. Nifedipine increased lethality compared with verapamil and propranolol.
对73例肥厚型心肌病(HC)患者研究了β受体阻滞剂(普萘洛尔、喷布洛尔)和钙拮抗剂(硝苯地平、维拉帕米、地尔硫䓬)的作用。评估了临床数据、心电图和超声心动图检查结果。发现β肾上腺素能阻滞剂和钙拮抗剂可改善三分之一患者的生活质量。喷布洛尔和硝苯地平可使一半患者的生活质量得到改善。β肾上腺素能阻滞剂和钙拮抗剂均不能减轻心肌肥厚。钙拮抗剂可能导致心肌收缩力降低,而β肾上腺素能阻滞剂可能增加射血分数。地尔硫䓬对舒张功能产生了积极作用,但有许多副作用。与维拉帕米和普萘洛尔相比,硝苯地平增加了致死率。